Summary & Overview
CPT 80341: Multidrug Antiepileptic (7+ Drugs) Panel
CPT code 80341 denotes a laboratory assay that detects or measures seven or more antiepileptic (anticonvulsant/antiseizure) medications in a single patient specimen. This multitarget panel supports therapeutic drug monitoring and toxicity screening for patients on complex antiseizure regimens. Nationally, such testing matters for epilepsy management, inpatient and outpatient monitoring, and coordination of care across neurology and pharmacy services. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find clinical context explaining when a broad antiepileptic panel is used, typical service settings, and operational considerations for laboratory processing. The publication also provides payer coverage context and commonly billed modifiers used with laboratory services. Where payer-specific policies exist, the report summarizes general approaches to prior authorization, medical necessity criteria, and coding guidance for broad-spectrum antiepileptic testing. Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes is noted as unavailable; the focus remains on the clinical purpose and billing context of CPT code 80341 and what providers and billing staff need to know about using this code for complex antiseizure medication panels.
Billing Code Overview
CPT code 80341 describes a laboratory test in which the analyst measures the amount of, or detects the presence of, seven or more antiepileptic (anticonvulsant/antiseizure) medications in a patient specimen. This service is a multitarget antiepileptic drug screen used to identify and quantify multiple antiseizure agents when the specific drugs being tested are not captured by other CPT codes.
Service Type: Laboratory testing — quantitative or qualitative antiepileptic drug panel
Typical Site of Service: Clinical laboratory or hospital laboratory setting, including outpatient laboratory draw stations and hospital laboratory processing areas.
Clinical & Coding Specifications
Clinical Context
A 28-year-old patient with refractory generalized epilepsy presents for therapeutic drug monitoring and medication compliance assessment after recent seizure clusters. The neurology provider orders a comprehensive antiepileptic drug panel to detect and quantify multiple anticonvulsant agents because the patient is taking several older and newer antiseizure medications and the specific drugs are not covered by single-drug assays. The specimen (serum or plasma) is collected in an outpatient phlebotomy clinic or hospital laboratory; the sample is transported to a reference laboratory with mass spectrometry capability. The laboratory analyst performs a multi-analyte qualitative/quantitative assay that measures the presence and amounts of seven or more antiepileptic medications to guide medication adjustments, identify drug interactions, confirm adherence, and investigate toxicity. Typical workflow steps include order entry by the neurologist, specimen collection by nursing or phlebotomy staff at an ambulatory clinic or inpatient unit, courier transport to the clinical lab, analytical testing by the laboratory using validated instrumentation (for example, LC-MS/MS), result verification by a lab director, and reporting to the ordering clinician for clinical interpretation and medication management decisions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When only the professional interpretation or supervision of the laboratory testing is billed separately from the technical component. |